Table 1.

Previous reports about myocardial necrosis marker in COVID-19 patients

	Patients with SARS-CoV-2 infection	Patients with abnormal cardiac biomarkers	Cardiac lesion biomarkers	Notes
Xu et al. [16]	53	30	LDH CK Myo TNT-HSST NT-proBNP	This study shows that cardiac abnormalities including elevated myocardial enzyme levels (56.6%) are common in COVID-19 patients
Wu et al. [5]	188	Abnormal hs-TNI 11.2% 68.6% LDH abnormal 76.1% α-HBDH abnormal Abnormal CK 11.2% Abnormal CK-MB 10.1%	hs-TNI CK CK-MB LDH α-HBDH	This study assessed the associations between heart injury indicators and mortality in COVID-19 patients and that high hs-TnI on admission can be associated with higher mortality
Bo Zhou et al. [26]	34	Abnormal c-TNI 8/8 in very severe group and 1/26 in severy group	c-TNI CK LDH α-HBDH	They found high percentage of increased cTnI levels in very severe COVID-19
Huang et al. [15]	41	Abnormal CK 13/40 (33%) Abnormal hs-TNI 5/41 (12%) Abnormal LDH 29/40 (73%)	LDH CK Hs-TNI	They report a cohort of 41 patients with laboratory confirmed 2019-nCoV infection
Chen et al. [29]	120	Abnormal c-TNI (n = 12, 10%) Abnormal NT-proBNP (n = 33, 27.5%)	NT-proBNP c-TNI	This study has shown condition of some patients with severe SARS-CoV-2 infection, patients might deteriorate rapidly a possible exitus was a fulminant myocarditis